Beam Therapeutics has the GF Score of 66, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Beam Therapeutics
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Beam Therapeutics (MEX:BEAM) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Beam Therapeutics GF Score Related Terms
MEX:BEAM vs ELVN, IDYA, PBLS: GF Score Comparison
For the Biotechnology subindustry, Beam Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's GF Score falls into.
Beam Therapeutics (MEX:BEAM) has a GF Score of 66 as of Jun. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Beam Therapeutics and its competitors. This is 89% above median its historical median of 35.00. Over the past decade, Beam Therapeutics' GF Score has ranged from 4.00 to 68.00.
Is Beam Therapeutics' GF Score too high?
Beam Therapeutics' current GF Score of 66 is 89% above median its 10-year median of 35.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 68.00. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' GF Score compare to ELVN and IDYA?
Beam Therapeutics' GF Score of 66 can be compared against companies in the Biotechnology industry. Historically, Beam Therapeutics' own GF Score has ranged from 4.00 to 68.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current GF Score is 66, which is 89% above median its own 10-year median of 35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN525.92, compared to a current price of MXN628.46 — trading 19.5% above its estimated fair value. The current GF Score is 66, which is 89% above median its 10-year median of 35.00. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current GF Score is 66 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 19.5% above its estimated GF Value™ of MXN525.92.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
GF Score: 66 (89% above median its 10-year median of 35.00)
GF Value™: MXN525.92 vs. price of MXN628.46 (19.5% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score
Get the complete analysis for MEX:BEAM
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 